Skip to main content
Home

Breadcrumb

  1. Home
  2. News
  3. Search results
Displaying results 226 - 250 of 643 Clear search
Zyme Communications
Lee Patterson, CEO, Metrion Biosciences
Healthcare and Life Science 20 Jan 2025

Metrion Biosciences listed in The Sunday Times 100 Tech, as one of Britain's fastest-growing private technology companies

Inaugural feature recognises companies within the UK technology sector, developing or selling a proprietary technology Listing is recognition of Metrion’s leadership position in preclinical ion channel drug discovery research services

Cambr

Zyme Communications
Bio-Rad Nuvia wPrime 2A Media
Healthcare and Life Science 14 Jan 2025

Bio-Rad launches Nuvia wPrime 2A media for biomolecule purification

Scalable Weak Anion Exchange and Hydrophobic Interaction (AEX-HIC) Mixed-Mode Chromatography Resin Enables Small- to Large-Scale Purification for Research and Biotherapeutic Applications

Zyme Communications
Sapio Sciences
Healthcare and Life Science 14 Jan 2025

Sapio Sciences announces enhanced capabilities for chemistry, immunogenicity, GMP and molecular biology

Sapio Lab Informatics Platform (Release 24.12) further optimizes productivity across lab workflows

Zyme Communications
Terumo Blood and Cell Technologies and FUJIFILM Irvine Scientific
Healthcare and Life Science 14 Jan 2025

Terumo Blood and Cell Technologies and FUJIFILM Irvine Scientific Collaborate to Accelerate T Cell Expansion for Cell Therapy Developers

Turnkey solution helps simplify and scale T cell expansion using Fujifilm's PRIME-XV® T Cell Expansion Media on Terumo BCT’s Quantum Flex™ Cell Expansion System, easing the burden for developers

Zyme Communications
Dr. Hazel Jones, CEO, Enhanc3D Genomics	Dr. Dan Turner, CSO, Enhanc3D Genomics
Healthcare and Life Science 14 Jan 2025

Enhanc3D Genomics launches suite of 3D multi-omics solutions to accelerate drug development

Solutions driven by proprietary, integrated multi-omics platform to support data-driven, faster and more precise drug discovery and development, to be introduced during JPM Week Provides customers with access to Enhanced’s 3D genomics technology and 3D Multi-Omic P
Zyme Communications
Pheno Therapeutics
Healthcare and Life Science 14 Jan 2025

Pheno Therapeutics granted clinical trial authorisation for lead multiple sclerosis therapeutic candidate PTD802

UK MHRA grants CTA for first-in-human trial of a selective GPR17 antagonist Small molecule therapeutic designed for treatment of neurological diseases such as multiple sclerosis

Edinburgh, UK, 14 January 2025: Pheno Therapeutics Li

Zyme Communications
Bio-Rad and Genoscopy
Healthcare and Life Science 08 Jan 2025

Geneoscopy closes $105M in Series C funding round to power next-generation of gastrointestinal diagnostic tests

Bio-Rad leads investment to support the launch of ColoSense®, a non-invasive colorectal cancer screening test, and advance diagnostic innovations for inflammatory bowel disease

Zyme Communications
Bio-Rad’s portfolio of Foresight Pro Columns: 5–33 cm inner diameter (ID) columns and new 45 cm ID column (largest column, back left)
Healthcare and Life Science 07 Jan 2025

Bio-Rad extends range of Foresight Pro prepacked chromatography columns for biotherapeutic production

Foresight Pro 45 cm ID Column Provides a Convenient and Reliable Solution for Purification of Biomolecules in Downstream Bioprocessing

Zyme Communications
www.closedloopmedicine.com
Healthcare and Life Science 17 Dec 2024

Closed Loop Medicine demonstrates application of digital platform for remote blood pressure and medication monitoring

Study published in JMIR validates the feasibility, use and safety of a digital platform for remote, routine monitoring of blood pressure and medication in hypertension patients Findings support the use of the Company’s combined drug + digital approach to inform and
Zyme Communications
Bio-Rad  iQ-Check
Healthcare and Life Science 16 Dec 2024

Bio-Rad receives NF validation for iQ-Check Listeria spp. and iQ-Check Listeria monocytogenes shortened enrichment protocol in all food products and environmental samples

HERCULES, Calif. — December 16, — 2024 Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostic products, announces that NF Validation (AFNOR) has approved the extension of certification of the iQ-Check™ Listeria spp.

Zyme Communications
FairJourney Biologics
Healthcare and Life Science 16 Dec 2024

FairJourney Biologics establishes Scientific Advisory Board

Global industry leaders appointed to define key avenues for growth, accelerate innovation, and optimize scientific strategies to maintain leadership in antibody discovery and development

Zyme Communications
Deep Science Ventures and General Inception
Healthcare and Life Science 12 Dec 2024

Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company

Combines Deep Science Ventures’ novel first-principles methodology and AI tools, with General Inception’s expertise in advancing early-stage innovations to drive scientific discovery and venture creation

Zyme Communications
SapioCon 2025
Healthcare and Life Science 10 Dec 2024

Accelerating Innovation in Research and Diagnostics with Science-Aware AI

SapioCon 2025 speaker line-up highlights AI's role in reshaping the lab of the future

Zyme Communications
Dr. Mark Carnegie-Brown, Chairman of the Board of Directors, Newcells Biotech,
Healthcare and Life Science 05 Dec 2024

Newcells Biotech raises additional funding from investors

Newcastle, UK, 5th December 2024: Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, announces it has raised a furt

Zyme Communications
Fairjourney Bio
Healthcare and Life Science 04 Dec 2024

FairJourney Biologics appoints Dr. Marc van Dijk as Chief Scientific Officer of Antibody Discovery and Engineering

Appointment of industry expert to drive innovation and excellence in antibody discovery and engineering, to support market demand from global pharma and biotech

Zyme Communications
Sapio logo
Healthcare and Life Science 03 Dec 2024

evitria Partners with Sapio Sciences to streamline antibody workflow management and reporting

Leading antibody expression service provider implements Sapio’s ELN and Report Builder for advanced sample tracking and data management

Zyme Communications
Orbit Discovery and Evergreen Theragnostics
Healthcare and Life Science 03 Dec 2024

Orbit Discovery and Evergreen Theragnostics expand research collaboration to advance targeted therapeutics development

Oxford, UK, and Springfield, NJ, USA, 3rd December 2024: Orbit Discovery, a leading provider of peptide discovery services, and Evergreen Theragnostics, a radiopharmaceutical company at the forefront of precision medicine, today announced an extension to their research

Zyme Communications
Centauri Therapeutics
Healthcare and Life Science 25 Nov 2024

Centauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives

Funding to support further development of lead programme for a novel therapeutic targeting Gram-negative bacteria including Multi-Drug-Resistant strains Optimisation will also support application of the Alphamer® platform across other therapeutic indicat
Zyme Communications
Lee Patterson, CEO, Metrion Biosciences
Healthcare and Life Science 25 Nov 2024

Metrion Biosciences appoints Lee Patterson as CEO

Significant CRO C-suite experience expected to drive growth and commercial expansion into global markets

Cambridge, UK, 25 November 2024: Metrion Biosciences, the specialist preclinical contract research organisation (CRO) and a leader in ion channe

Zyme Communications
Winners of the OBN Awards 2024
Healthcare and Life Science 21 Nov 2024

Shining a light on the life sciences

The OBN Awards struck an optimistic tone as the best of the UK’s life sciences industry was celebrated

Zyme Communications
Spheroid confocal spinning disk (left) and holotomography acquisitions (right).
Healthcare and Life Science 20 Nov 2024

CrestOptics and Tomocube partner to advance 3D imaging with new multimodal imaging platform

First commercially available spinning-disk confocal holotomographic instrument, enabling advanced 3D imaging with fluorescence-based detection New system showcased at SPAOM24 (20th-22
Zyme Communications
The Tagomics team
Healthcare and Life Science 20 Nov 2024

Tagomics announces a multiomic profiling co-marketing agreement with Agilent

Exclusive program will provide customers with a single, unified workflow for comprehensive genomic profiling and genome-wide epigenetic analysis

Zyme Communications
Asimov and RevOpsis Therapeutics
Healthcare and Life Science 20 Nov 2024

Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line

Strategic agreement will accelerate the manufacturing of fully human multispecific therapies for chronic retinal diseases with high unmet need using Asimov’s CHO Edge System

Zyme Communications
Steritas LLC
Healthcare and Life Science 20 Nov 2024

Steritas announces collaboration with argenx to advance evidence for novel steroid-sparing therapeutics

First-in-class steroid-toxicity outcome assessments licensed by argenx to support development of novel steroid-sparing therapeutics for autoimmune diseases

Zyme Communications
Enterprise Therapeutics
Healthcare and Life Science 19 Nov 2024

Enterprise Therapeutics publishes on medicinal chemistry of ETD001, a novel inhaled ENaC blocker for treatment of cystic fibrosis

Paper in the European Journal of Medicinal Chemistry discloses the optimisation process leading to the selection for development of ETD001, an inhaled ENaC blocker with a best-in-class profile ETD001 commenced Phase 2 clinical study in people with cystic fibrosis in Jul

Pagination

  • First page «
  • Previous page ‹
  • …
  • Page 8
  • Page 9
  • Current page 10
  • Page 11
  • Page 12
  • …
  • Next page ›
  • Last page »
Receive our newsletter

Cambridge Network Limited is a company registered in England under company No. 3400152

The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

Email: [email protected], Tel: 01223 746801

© 2026 Cambridge Network. All Rights Reserved.

Website by KISS